ngm120
ngm120: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| NGM BIOPHARMACEUTICALS INC (NGM) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Frequently asked questions
Who is developing ngm120?
ngm120 is being developed by NGM BIOPHARMACEUTICALS INC.
How many clinical trials involve ngm120?
BioSniper tracks 1 clinical trial involving ngm120.
Get deeper analysis on ngm120
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis